Form 4: Avenue Therapeutics Director Sells Shares Following Reverse Stock Split

Avenue Therapeutics director Neil Herskowitz sold 23 shares of common stock at $2.97 per share on December 2, 2024.

Summary

• Neil Herskowitz, a director at Avenue Therapeutics, sold 23 shares of the company's common stock on December 2, 2024.
• The sale was executed at a price of $2.97 per share.
• This transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
• The number of shares has been adjusted to reflect a one-for-seventy-five reverse stock split that took place on April 26, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are a common practice for all publicly traded companies in the US, ensuring transparency of insider trading.
• The reverse stock split is a common corporate action, often used to increase the share price and meet listing requirements.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on investor sentiment.

Key Dates

Keywords

Form 4, insider trading, stock sale, Neil Herskowitz, Avenue Therapeutics, ATXI, reverse stock split